Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (237)	1/11/2000 12:54:00 PM
From: biowa	Read Replies (1) \| Respond to of 557

Mike, Stewart Parker gave a excellent presentation this morning. In a nutshell (hopefully I can expand later) 1) tgAAV-CFTR - CF PII aerosol trial to commence this year (and present/publish PI aero results) 2) E1A works great as a monotherapy, the preclinical results in combo with taxol are outstanding. Therefore this year should see PII monotherapy trials in Ovarian cancer initiate, next year should see trials in combo. They'll publish/present Head & Neck PII results this year (she showed one CR response image). 3) Pre-clinical programs mentioned include E1A in metastatic cancer, AAV candidates in hemophilia A (entering clinic 2001), cardiovascular disease, and RA. 4) 5 collaborations currently, and she "expects to continue the trend of doing the most deals in gene therapy." "Stay tuned" for more deals this year. 5) They believe they are the only co. with the capability to produce AAV vectors in large-scale quantities (I suspect Avigen might argue). Sorry so short, biowa